RE:FDA Comment: THe FDA is concerned with MCNA's efficacy, independent of prior treatment.
Is seems from their point, they wonder if the prior treatment with BCG is positively affecting the MCNA mechanism of action within the second line patient pool.
This is an important question, becuase if MCNA was given off label to BCG naive populations, then the MCNA efficacy could suffer as a result.